Epigenetics targeted protein-vorinostat nanomedicine inducing apoptosis in heterogeneous population of primary acute myeloid leukemia cells including refractory and relapsed cases

Aberrant histone deacetylation is crucial for the onset and progression of acute myeloid leukemia. Herein, we report an albumin bound vorinostat nanomedicine (~ 100 nm) exhibiting enhanced cellular uptake and exceptional single-agent activity against the clonogenic proliferative capacity of bone marrow derived leukemic cells from a heterogenous set of patient samples, sparing healthy cells. This epigenetics targeted nanomedicine appears to be a promising therapeutic strategy against AML patients from various French-American-British classes, where it may be used as a stand-alone drug or as an adjuvant together with the classic chemotherapeutic regime of cytarabine and daunorubicin.264